Stéphane Bancel is a French billionaire businessman and the CEO of Moderna Therapeutics, a clinical stage biotechnology company.
Bancel joined Moderna’s board of directors in 2011, the same year he was brought on as CEO. The biotech company focuses on the discovery and development of messenger RNA therapeutics and vaccines for infectious, immuno-oncology and cardiovascular diseases.
With Bancel at the helm during the COVID-19 global pandemic, Moderna was one of the first two vaccine developers to receive authorization in the United States. Moderna’s stock price rose in response to the success of the world’s first mRNA vaccine, making Bancel’s stake in the company worth over $1 billion.
Prior to Moderna, Bancel was the CEO of French diagnostics company, bioMérieux, from 2007-2011. While leading the company, he accelerated bioMérieux’s sales growth rate by pivoting to high-value biomarkers, as well as nearly doubling its market capitalization despite the financial crisis.
He gained experience in the pharmaceutical industry through roles at Eli Lilly including managing director, Belgium and executive director, global manufacturing strategy and supply chain.
Bancel was elected one of the World Economic Forum’s Young Global Leaders in 2009, Best CEO for Investor Relations in France in 2009, and #1 CEO in the biotechnology sector according to the 2011 Thomson Reuters Pan European EXTEL Study.
Bancel sits on the boards of Qiagen N.V. and Indigo, and he is a venture partner at Flagship Pioneering as well as a trustee for Boston’s Museum of Science. He earned his Master of Engineering degree at École Centrale Paris, his M.S. in chemical engineering at the University of Minnesota, and his M.B.A. at Harvard Business School.